LigaChem Bioscience, formerly known as LegoChem Bioscience, held a gathering on April 16th to share insights into its global technology transfer strategy. The event, hosted by Daily Partners, showcased the company's achievements since signing a significant technology transfer agreement with Janssen Biotech last year.

During the event, CEO Sejin Park highlighted LigaChem Bioscience's success in the field of antibody-drug conjugates (라이브바카라), noting that the company has received accolades at the World 라이브바카라 Summit for five consecutive years. Park emphasized the company's track record of securing 13 global technology transfers, including partnerships with industry leaders such as Janssen Biotech, Amgen, and Takeda Pharmaceuticals.

Looking ahead, Park outlined the company's strategic shift towards becoming a 'First Mover' in the 라이브바카라 therapeutics sector. He expressed the company's ambition to transition from a platform-centered approach to developing an independent 라이브바카라 pipeline, aiming to secure five Phase 1 clinical pipelines within the next five years.

He mentioned, "The company aims to secure five independent Phase 1 clinical pipelines within the next five years, with the goal of technology transfer thereafter. Additionally, we plan to explore 2-3 pipelines over the course of a year, implementing a strategy for both in-house clinical trials and technology transfer." He added, "In order to achieve these strategies, we successfully secured a $117 million investment in September 2021. Especially, we have set a strategy to achieve 'Vision 2030' ahead of schedule by the end of last year."

LigaChem Bioscience has devised two strategies to achieve Vision 2030 ahead of schedule: accelerating the development of new candidate molecules and conducting simultaneous in-house clinical trials and technology transfers. CEO Park emphasized, "Our goal is to propel to the forefront of ADC companies by rapidly acquiring multiple clinical pipelines and forming strategic partnerships with global pharmaceutical firms," further stating, "This approach will enable us to widen the gap with our competitors."

On January 15th, Orion announced a $401 million investment to secure a 25% stake in LigaChem Bioscience. By March 29th, Orion had completed the $400 million payment for a 25.73% stake, thus becoming the largest shareholder.

With Orion's substantial investment, LigaChem Bioscience now holds approximately $510 million in cash. Furthermore, it anticipates receiving a $2 billion milestone payment for exercising exclusive development rights from Janssen Biotech next year. Leveraging this financial position, LigaChem plans to secure $729 million in research and development (R&D) funds, aiming to emerge as a leading global 라이브바카라 biotech company.

In a conversation with HitNews in January, CEO Park revealed, "Over the past 4-5 years, the company has actively sought partners for new drug development," noting, "The deal with Orion was finalized within a month after several meetings between the CEOs, following their initial encounter on December 1st of last year."

CEO Park also discussed the technology transfer model, stating, "After establishing clear goals, flexible business strategies should be developed based on the company's resources, funding, and business environment." He elaborated, "LigaChem employs various technology transfer models, including third-party outsourcing, regional divisional technology transfer, NRDO (No Research Development Only), joint ventures, research and option, joint development and option, and joint development and profit sharing."

Highlighting the importance of Business Development (BD) teams, Park emphasized, "Expanding a dedicated technology transfer organization is imperative. BD teams are equally vital as R&D teams, particularly those with global capabilities." He advised, "Establishing trust with global companies is paramount. During technology commercialization, negotiations between the company and its partners can lead to the creation of new models that meet the needs of both parties."